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Abstract
Background: Tumours are not only composed of malignant cells but also consist of a stromal micro-environment,
which has been shown to influence cancer cell behaviour. Because the ageing process induces accumulation of
senescent cells in the body, this micro-environment is thought to be different in cancers occurring in old patients
compared with younger patients. More specifically, senescence-related fibroblastic features, such as the senescence-
associated secretory profile (SASP) and the induction of autophagy, are suspected to stimulate tumour growth and
progression.
Methods: We compared gene expression profiles in stromal fields of breast carcinomas by performing laser capture
microdissection of the cancer-associated stroma from eight old (aged ≥80 years at diagnosis) and nine young
(aged <45 years at diagnosis) patients with triple-negative breast cancer. Gene expression data were obtained
by microarray analysis (Affymetrix). Differential gene expression and gene set enrichment analysis (GSEA) were
performed.
Results: Differential gene expression analysis showed changes reminiscent of increased growth, de-differentiation and
migration in stromal samples of older versus younger patients. GSEA confirmed the presence of a SASP, as well as the
presence of autophagy in the stroma of older patients.
Conclusions: We provide the first evidence in humans that older age at diagnosis is associated with a different stromal
micro-environment in breast cancers. The SASP and the presence of autophagy appear to be important age-induced
stromal features.
Keywords: Breast cancer, Stroma, Senescence, Senescence-associated secretory profile, Autophagy, Gene expression,
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Background
Oncological research over the past decades has been fo-
cussed primarily tumour cell characteristics. However,
tumoural masses are not exclusively composed of ma-
lignant cells; they also comprise a stromal component
containing endothelial cells, (myo)fibroblasts, smooth
muscle cells, adipocytes and inflammatory cells. Research
on the stromal component of tumour masses has shown
that stromal characteristics are correlated with disease out-
come and behaviour [1–10] in several malignancies. The
stroma seems to play a very important role in tumour initi-
ation, progression and metastatic spread [11, 12]. The fibro-
blasts contained in this stromal compartment show a
specific phenotype and are called carcinoma-associated
fibroblasts [13]. Because cellular senescence progressively
occurs throughout a person’s lifetime in fibroblasts of
various origins [14], it seems plausible that the charac-
teristics of the stromal compartment of breast cancers
would differ between young and older patients and that
this could result in a pro-tumourigenic micro-
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environment with stimulation of proliferation, migra-
tion/invasion and de-differentiation.
The incidence of breast cancer, the most frequent tumour
occurring in women, increases with age [15, 16]. Cancer in
older patients is thought to arise from lifelong exposure to
harmful stimuli, such as DNA-damaging agents, oxidative
stress factors and telomeric loss. In addition, the micro-
environmental changes caused by senescent cells might
also be an important harmful trigger. Breast cancer in
young patients usually reflects either a genetic defect or
the impact of early life-transforming effects on an imma-
ture breast epithelium.
Senescence in general is a protective mechanism that
shuts down damaged cells [17]. Nature has selected for
this mechanism to protect young organisms from devel-
oping cancer. Senescent cells are forced into a state of
irreversible growth arrest [18, 19] and exhibit a specific
phenotype characterised by enlarged size, flattened morph-
ology, senescence-associated β-galactosidase activity, reor-
ganisation of chromatin into foci of heterochromatin and
resistance to apoptosis [20]. They also acquire the so-called
senescence-associated secretory profile (SASP) [21, 22],
maintaining the growth arrest and recruiting immune
cells towards the damaged cells in order to eradicate
them. However, the SASP also seems to have a detrimen-
tal influence on nearby cells. Epithelial cells neighboured
by senescent fibroblasts lose differentiated properties,
become invasive and undergo full malignant transform-
ation [20, 23–25]. In this process, a major role has been
attributed to matrix metalloproteinase 3 [23] together
with other components of the SASP [25, 26], such as
inflammatory cytokines and chemokines. This concept
of senescence as a useful cancer-protective mechanism
in younger life but a detrimental cancer-promoting
mechanism in later life has repeatedly been described
as an example of ‘antagonistic pleiotropy’ [27, 28] in
cellular or animal models [23, 24, 29–32]. Senescent
cells have been reported in vivo in a variety of tissues of
different organisms, including mice, primates and humans
[14, 33–36]. Also, studies have provided evidence that in-
creasing age does result in a higher frequency of senescent
cells [14, 33, 34, 37], albeit mostly in the skin.
An additional mechanism that has been proposed to
explain the tumour-promoting effects of a senescent
micro-environment is the ‘the autophagic tumor stroma
model of cancer’ [38–42]. This model states that fibroblasts,
in transition to a senescent state, activate the autophagic
process. During this so-called autophagy-to-senescence
transition (AST), the cells shift towards an aerobic gly-
colysis metabolism, creating high-energy mitochondrial
fuels that feed the nearby epithelial cancer cells. Autophagic
fibroblasts were shown to have tumour- and metastasis-
promoting activity [39]. The discovery of this concept was
preceded by the finding that tumoural cells can induce
AST in surrounding fibroblasts by secreting hydrogen
peroxide that causes oxidative stress and activation of au-
tophagy in the fibroblasts. This process was named the re-
verse Warburg effect (as opposed to the original idea, called
the Warburg effect, by which aerobic glycolysis takes place
in epithelial cancer cells). Fibroblasts displaying a constitu-
tively activated autophagy programme turned out to show
many morphological characteristics of senescence,
including induction of P21WAF1/CIP1, which led to the
hypothesis that AST is one of the mechanisms by which
senescent stromal cells create a ‘fertile soil’ for the initiation
and progression of cancer.
Despite this knowledge, stromal differences with increas-
ing patient age have so far never been investigated in vivo,
and little clinical evidence can be found for a more aggres-
sive behaviour of tumour cells growing in a context of
‘older’ stroma. On the contrary, breast cancers in older
patients have in general been shown to grow more slowly
and to behave less aggressively, even when adjusting for dif-
ferent histological tumour characteristics [43, 44]. On these
premises, we sought to compare gene expression profiles of
tumour-adjacent stroma in older versus younger patients
with breast cancer matched for other clinico-pathologic
parameters.
Methods
Patient selection and clinical specimens
This study was approved by the ethics committee of the
University Hospitals Leuven (Leuven, Belgium) in accord-
ance with the International Conference on Harmonisation
Harmonised Tripartite Guideline for Good Clinical
Practice. Candidate patients were selected using the
following criteria: (1) aged <45 years or ≥80 years, (2)
no neo-adjuvant chemotherapy treatment or hormone
treatment before surgery, (3) surgery for early triple-negative
breast cancer (defined as oestrogen receptor [ER] and pro-
gesterone receptor [PR] <1% and human epidermal growth
factor receptor 2 [HER2] <2+ by immunohistochemistry or
fluorescent in situ hybridisation-negative) with fresh frozen
resection specimens available (stored at −80 °C at the path-
ology department of the University Hospitals Leuven) and
(4) no chronic inflammatory diseases to exclude confound-
ing variables.
For each candidate patient, one section of the frozen
tumour material was obtained for hematoxylin and eosin
(H&E) staining. H&E-stained sections were evaluated for
tumoural and stromal content and used to localise the
best areas for stromal microdissection (see Fig. 1 as an
example). Only tumour tissue blocks consisting of invasive
tumour with representative carcinoma-associated stromal
fields to allow laser capture microdissection (LSM)
were selected. We selected tumours with a very low
amount of or absent tumour-infiltrating lymphocytes to
prevent bias in the gene expression analyses. On the
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basis of the above criteria, 17 female patients with breast
cancer (9 young patients <45 years old at diagnosis
and 8 old patients ≥80 years old at diagnosis) were
included in the study.
Staining procedures and laser capture microdissection
Preparation of the tissue slides
For the selected patients, ten frozen sections of 10-μm
thickness were mounted onto specific membrane slides
(steel frames with polyethylene terephthalate membrane,
catalogue number 11505151; Leica Microsystems, Wetzlar,
Germany) and were kept at −80 °C until the staining and
dissection procedure was started. All tissue slides under-
went LCM within 7 days after preparation.
Staining
Prior to LCM, tumour slides were stained with cresyl
violet following a procedure optimised for maximising
RNA yield. Briefly, tumour slides were taken from −80 °C
and were fixed into a 95% ethanol solution for 30 seconds.
Next, they were transferred to ethanol solutions with
progressively decreasing concentrations (75%, 50%) for
30 seconds each. Then, cresyl violet dye (cresyl violet
acetate pure high-purity biological stain, catalogue number
AC229630050; Acros Organics, Geel, Belgium) at a concen-
tration of 0.2% was applied for 30–60 seconds, after which
dehydration of the tissue was achieved by rinsing the slides
with increasing concentrations of ethanol (50%, 75%, 95%,
100%, 100%) for 15 seconds each.
Laser capture microdissection
After the staining procedure, LCM was accomplished
within 30 minutes by using a laser microscope (LMD6500;
Leica Microsystems). Dissected stromal pieces were im-
mediately collected in an RNase/DNase-free capture vial
containing 25 μl of stabilising RNA extraction buffer.
During dissection, care was taken to avoid blood vessels,
zones containing infiltrating immune cells, or fatty tissue.
Dissection was restricted to fields contained within the
perimeter of the invasive tumour or at the invasive front
of the tumour, but in direct relationship with invasive
epithelial nests. Pictures were taken before and after the
dissection procedure (see Fig. 2 as an example). After
finishing dissection for one tumour slide, 25 μl of RNA ex-
traction buffer was added to the capture vial, and lysis was
performed for 30 minutes at 42 °C. The obtained lysate
was stored at −80 °C until further RNA extraction. For
each patient, several tumour slides were laser-dissected
using this procedure (seven to ten slides per patient ac-
cording to size and amount of stromal fields within the
tumour tissue).
RNA extraction and amplification
RNA isolation was performed using the Arcturus PicoPure
RNA extraction kit (PicoPureTM Frozen RNA Isolation Kit,
catalogue number KIT0202/KIT0204; Arcturus, Mountain
View, CA, USA) according to the manufacturer’s protocol.
Briefly, lysates from the same tumour were combined, and
after addition of 50 μl of ethanol 70%, the pooled samples
were passed onto pre-conditioned RNA extraction col-
umns. After centrifugation and washing, DNase was
applied onto the column to eliminate residual DNA
(RNase-Free DNase Set, catalogue number 79254; QIAGEN,
Hilden, Germany). After a washing step, the purified RNA
was eluted from the column using 11 μl of elution buffer.
Samples were subsequently tested for RNA quality (RNA
Quality Indicator) on the Experion™ system (Bio-Rad
Laboratories, Hercules, CA, USA) using high-sensitivity
RNA chips, and concentrations were measured using
the NanoDrop 2000 spectrophotometer (Thermo Scientific,
Wilmington, DE, USA). The quality of the RNA varied
between samples, which is a known limitation of the LSM
procedure [45] (see Additional file 1). Prior to microarray
analysis, RNA was pre-amplified using the Ovation PicoSL
WTA System V2 (catalogue number 3312-24; NuGEN,
Leek, The Netherlands). The Ribo-SPIA (single-primer
isothermal amplification) technology implemented in
this procedure is ideal for amplification of partially
degraded and compromised RNA samples, contributes
minimal coverage bias, and is highly reproducible [46].
The procedure is widely used in LCM projects and does
not introduce significant bias into relative gene expression
values [47, 48]. A clean-up step using the MinElute
Reaction Cleanup Kit (catalogue number 28204; QIAGEN)
was also incorporated into the amplification procedure.
After NuGEN pre-amplification of the RNA samples, quan-
titative reverse transcription-polymerase chain reaction as-
sessment of common housekeeping genes showed that the
Fig. 1 Haematoxylin and eosin-stain of selected tumour block for
laser capture microdissection
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amplification procedure had resulted in highly concentrated
complementary DNA fragments with sufficient size to be
recognised by the primers (data not shown).
Gene expression analysis
Gene expression was analysed using Human Genome
U133Plus2 microarray chips (Affymetrix, Santa Clara,
CA, USA) at the J.C. Heuson Breast Cancer Translational
Research Laboratory (Jules Bordet Institute, Brussels,
Belgium) according to the manufacturer’s instructions.
Standard quality assessments were conducted on the
resulting files, and all samples passed quality assurance
for further analysis. Expression values were computed
using the frozen robust multi-array analysis (fRMA)
normalisation method (‘frma’ package in Bioconductor)
[49]. When multiple probe sets mapped to the same
official gene symbol, we computed their average value.
The expression data are available from the Gene Ex-
pression Omnibus (GEO) repository under accession
number [GEO:GSE90521].
Statistical analysis
Differential expression analysis
To identify the genes that were differentially expressed
in the two age categories (<45 years versus ≥80 years),
we computed for each probe set the mean expression
value in both age groups and calculated the fold change
of these means (i.e., the ratio of the average expression
of this particular gene in young and old patients). We
used a Wilcoxon test. Genes with fold change greater
than 1.5 or less than −1.5 were considered differentially
expressed.
In silico validation
To validate the obtained differential gene expression,
gene expression data sets from other projects in which
researchers investigated laser-dissected stromal samples
obtained from patients with breast cancer were retrieved.
The data sets were available in the National Center for
Biotechnology Information (NCBI) GEO database under
accession numbers [GEO:GSE5847] [9], [GEO:GSE4823]
[7] and [GEO:GSE14548] [8].
Gene set enrichment analysis
Gene set enrichment analysis (GSEA) was conducted
using our local reimplementation of the GSEA algorithm
developed at the Broad Institute [50]. Briefly, genes were
ranked according to their fold change in young versus
old patients, and an enrichment score (ES) ranging from −1
to 1 was computed. This score reflects to what extent the
genes constituting a given reference class are enriched
among the top up- or down-regulated genes of the differen-
tial expression analysis. Low (negative) ES values corres-
pond to an enrichment of the reference class among genes
that are up-regulated in old patients, whereas high
(positive) ES values correspond to an enrichment of the
reference class among genes that are up-regulated in
young patients. The false discovery rate-adjusted p
values associated with each ES value reflect the prob-
ability that an ES at least as high or as low could be
obtained merely by chance. Adjusted p values <0.05
were considered significant.
Results
Patient demographics
For the purpose of the present study, 17 female patients
(9 young patients <45 years old at diagnosis and 8 old
Fig. 2 Laser capture microdissection of cancer associated stroma. a–c Microdissection procedure. d Yield of stromal pieces after repeated
microdissection within the same tumour slide
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patients aged ≥80 years at diagnosis) with available fresh
frozen breast cancer resection specimens and with suffi-
cient stroma to allow laser microdissection were selected.
Extreme age categories were chosen to maximise the
probability of detecting significant age-related differences.
All patients underwent surgery for early breast cancer at
the Multidisciplinary Breast Center (University Hospitals
Leuven, Belgium) between 2000 and 2011. All patients
had invasive ductal carcinomas >1.5 cm and were negative
for ER, PR and HER2. Additional patient and tumour
characteristics are summarised in Table 1. The choice
of triple-negative breast cancers was made to exclude
cancer-related confounding factors as much as possible.
Differential gene expression analysis
A differential gene expression analysis using a 1.5-fold
up- or down-regulation as the cut-off revealed 120 genes
that were up-regulated in older subjects’ stromal samples
and 107 genes that were down-regulated in older sub-
jects’ stromal samples compared with younger subjects
(Table 2). Heat maps constructed using the 25 top up-
and down-regulated genes are shown in Fig. 3.
Data validation
We used publicly available data sets ([GEO:GSE5847]
[9], 34 samples; [GEO:GSE4823] [7], 33 samples;
[GEO:GSE14548] [8], 9 samples) to validate our find-
ings because of the limited size of our study group.
We found a significant overlap for ten genes, of which five
showed higher expression in older patients (p < 0.01) and
five showed lower expression in older patients (p < 0.01).
Venn diagrams depicting the overlapping genes are
shown in Fig. 4; gene details are listed in Table 3.
Gene set enrichment analysis
Next, we performed GSEA to measure the expression of
pre-defined gene sets related to specific biological pro-
cesses. The resulting ES, which ranges from −1 to 1, reflects
the enrichment in genes of a given reference class among
the top up- or down-regulated genes from the individual
gene ranking. Plots are shown in Figs. 5 and 6. The genes
that were included in each GSEA, with respective literature
references, are listed in Table 4.
Senescence genes
In the individual gene expression analysis, no significant
difference was found for genes known to be associated with
senescence, such as CDKN1A, CDKN2A, TP53, GLB1 or
the retinoblastoma (RB) genes. Nevertheless, the enrich-
ment analysis for this gene set resulted in an ES of −0.53,
suggesting enrichment of senescence genes in the stroma
of older patients, although statistical significance was not
reached (p = 0.09) (Fig. 5a). The lack of significance might
be due to the small sample size of the reference classes.
DNA damage response
None of the three most important components of the
DNA damage response, namely ATM, NBN (NBS1) and
CHK2, were differentially expressed between young and
Table 1 Patient and tumour characteristics
Patient Age at diagnosis (years) ER PR HER2 Tumour type Tumour grade Maximum tumour size (cm) pT stage pN stage
6 27 Neg Neg Neg Ductal 3 2.3 2 0
5 30 Neg Neg Neg Ductal 3 2.5 2 0
7 32 Neg Neg Neg Ductal 3 2.2 2 0
1 33 Neg Neg Neg Ductal 3 2.8 2 0
3 39 Neg Neg Neg Ductal 3 3.0 2 0
2 43 Neg Neg Neg Ductal 3 3.0 2 2a
4 44 Neg Neg Neg Ductal 3 2.8 2 0
8 44 Neg Neg Neg Ductal 3 3.5 2 0
9 44 Neg Neg Neg Ductal 3 3.0 2 0
12 80 Neg Neg Neg Ductal 3 4.0 2 0
16 82 Neg Neg Neg Ductal 3 3.5 2 0
17 82 Neg Neg Neg Ductal 3 1.5 1c 0
13 82 Neg Neg Neg Ductal 2 3.0 2 3a
15 83 Neg Neg Neg Ductal 3 3.8 2 1a
10 83 Neg Neg Neg Ductal 3 3.2 2 0
11 86 Neg Neg Neg Ductal 3 3.0 2 0
14 87 Neg Neg Neg Ductal 3 2.0 1c 0
Abbreviations: pT pathological T stage, pN pathological N stage, ER Oestrogen receptor, PR Progesterone receptor, HER2 Human epidermal growth factor receptor 2
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Table 2 Genes with greater than 1.5-fold or less than −1.5-fold
expression and respective fold changes
Gene Full name Fold
change
SPP1 Secreted phosphoprotein 1 −4.79
EPCAM Epithelial cell adhesion molecule −4.02
IL8 Interleukin 8 −2.74
NR4A2 Nuclear receptor subfamily 4, group A,
member 2
−2.45
RGS2 Regulator of G-protein signaling 2, 24 kDa −2.41
TREM1 Triggering receptor expressed on myeloid cells 1 −2.36
PROM1 Prominin 1 −2.27
SCG2 Secretogranin II −2.22
LPL Lipoprotein lipase −2.20
SDC4 Syndecan 4 −2.19
SLC2A3 Solute carrier family 2 (facilitated glucose
transporter), member 3
−2.13
PFKFB3 6-Phosphofructo-2-kinase/fructose-2,6-
biphosphatase 3
−2.11
TNFRSF11B Tumour necrosis factor receptor superfamily,
member 11b
−2.11
WIF1 WNT inhibitory factor 1 −2.10
NAMPT Nicotinamide phosphoribosyltransferase −2.08
ENPEP Glutamyl aminopeptidase (aminopeptidase A) −2.07
ZNF331 Zinc finger protein 331 −2.07
ANXA3 Annexin A3 −2.06
HAPLN1 Hyaluronan and proteoglycan link protein 1 −2.05
CSN3 Casein kappa −2.05
KRT23 Keratin 23 (histone deacetylase inducible) −2.05
VEGFA Vascular endothelial growth factor A −2.03
STC1 Stanniocalcin 1 −2.01
EGLN3 Egl nine homolog 3 (C. elegans) −1.97
ADM Adrenomedullin −1.96
G0S2 G0/G1 switch 2 −1.95
BAMBI BMP and activin membrane-bound inhibitor
homolog (Xenopus laevis)
−1.93
TDO2 Tryptophan 2,3-dioxygenase −1.93
CD24 CD24 molecule −1.92
DNER Delta/Notch-like epidermal growth factor-
related receptor
−1.92
IBSP Integrin-binding sialoprotein −1.91
HSPA2 Heat shock 70 kDa protein 2 −1.90
ERRFI1 ERBB receptor feedback inhibitor 1 −1.89
MUCL1 Mucin-like 1 −1.89
APOLD1 Apolipoprotein L domain containing 1 −1.89
SHISA2 Shisa homolog 2 (Xenopus laevis) −1.88
GPX3 Glutathione peroxidase 3 (plasma) −1.87
SERPINE1 Serpin peptidase inhibitor, clade E (nexin,
plasminogen activator inhibitor type 1),
member 1
−1.87
COL2A1 Collagen, type II, α 1 −1.86
Table 2 Genes with greater than 1.5-fold or less than −1.5-fold
expression and respective fold changes (Continued)
CP Ceruloplasmin (ferroxidase) −1.85
COL9A3 Collagen, type IX, α 3 −1.85
ENO2 Enolase 2 (gamma, neuronal) −1.84
FOSB FBJ murine osteosarcoma viral oncogene
homolog B
−1.84
TSPAN13 Tetraspanin 13 −1.82
CYP4X1 Cytochrome P450, family 4, subfamily X,
polypeptide 1
−1.82
TFAP2C Transcription factor AP-2γ (activating enhancer
binding protein 2γ)
−1.81
EGR3 Early growth response 3 −1.81
SOX11 SRY (sex-determining region Y), box 11 −1.79
CLEC5A C-type lectin domain family 5, member A −1.78
CYP26B1 Cytochrome P450, family 26, subfamily B,
polypeptide 1
−1.78
SLPI Secretory leukocyte peptidase inhibitor −1.78
PI15 Peptidase inhibitor 15 −1.78
RBP7 Retinol binding protein 7, cellular −1.77
SERPINA3 Serpin peptidase inhibitor, clade A (α-1
antiproteinase, antitrypsin), member 3
−1.77
CCDC102B Coiled-coil domain containing 102B −1.75
MTHFD2 Methylenetetrahydrofolate dehydrogenase
(NADP+ dependent) 2, methenyltetrahydrofolate
cyclohydrolase
−1.74
CFI Complement factor I −1.74
FCGBP Fc fragment of IgG binding protein −1.73
GPNMB Glycoprotein (transmembrane) NMB −1.73
FCGR2A Fc fragment of IgG, low affinity IIa, receptor
(CD32)
−1.72
MAL2 Mal, T-cell differentiation protein 2 −1.72
UAP1 UDP-N-acteylglucosamine pyrophosphorylase 1 −1.71
IER3 Immediate early response 3 −1.70
COL4A1 Collagen, type IV, α 1 −1.69
EFNB2 Ephrin-B2 −1.69
FCGR2B Fc fragment of IgG, low affinity IIb, receptor
(CD32)
−1.69
BTBD3 BTB (POZ) domain containing 3 −1.68
FGF13 Fibroblast growth factor 13 −1.68
GALNT3 UDP-N-acetyl-α-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 3 (GalNAc-T3)
−1.67
INHBB inhibin, β B −1.66
MANSC1 MANSC domain containing 1 −1.65
DSP Desmoplakin −1.64
CLDN8 Claudin 8 −1.64
TUBB2B Tubulin, β 2B −1.64
PODXL Podocalyxin-like −1.63
EHF ETS homologous factor −1.63
TIPARP TCDD-inducible poly(ADP-ribose) polymerase −1.63
ANGPT2 Angiopoietin 2 −1.62
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Table 2 Genes with greater than 1.5-fold or less than −1.5-fold
expression and respective fold changes (Continued)
ADAMTS1 ADAM metallopeptidase with thrombospondin type
1 motif, 1
−1.62
GPR4 G protein-coupled receptor 4 −1.61
DBH Dopamine β-hydroxylase (dopamine β-
monooxygenase)
−1.61
GPR183 G protein-coupled receptor 183 −1.61
TFAP2A Transcription factor AP-2 α (activating
enhancer binding protein 2 α)
−1.60
SNORD89 Small nucleolar RNA, C/D box 89 −1.60
CXCL2 Chemokine (C-X-C motif) ligand 2 −1.60
CXADR Coxsackie virus and adenovirus receptor −1.60
TPRKB TP53RK binding protein −1.60
ETS2 v-ets erythroblastosis virus E26 oncogene
homolog 2 (avian)
−1.60
RAPH1 Ras association (RalGDS/AF-6) and pleckstrin
homology domains 1
−1.60
ADGRF5 Adhesion G protein-coupled receptor F −1.60
CA2 Carbonic anhydrase II −1.59
LIPA Lipase A, lysosomal acid, cholesterol esterase −1.59
PGM2 Phosphoglucomutase 2 −1.59
KRT19 Keratin 19 −1.58
MGAT5 Mannosyl (α-1,6-)-glycoprotein β-1,6-N-acetyl-
glucosaminyltransferase
−1.58
NCF2 Neutrophil cytosolic factor 2 −1.57
RHOU Ras homolog gene family, member U −1.57
ALCAM Activated leukocyte cell adhesion molecule −1.57
LRRN1 Leucine-rich repeat neuronal 1 −1.57
OLR1 Oxidized low-density lipoprotein (lectin-like)
receptor 1
−1.55
SLC19A2 Solute carrier family 19 (thiamine transporter),
member 2
−1.55
PRPS2 Phosphoribosyl pyrophosphate synthetase 2 −1.55
MEGF10 Multiple EGF-like domains 10 −1.55
CYYR1 Cysteine/tyrosine-rich 1 −1.54
PLVAP Plasmalemma vesicle-associated protein −1.54
TM4SF1 Transmembrane 4 L6 family member 1 −1.54
PDGFA Platelet-derived growth factor α polypeptide −1.54
YBX2 Y box binding protein 2 −1.54
ATP2B1 ATPase, Ca2+-transporting, plasma membrane 1 −1.54
PCDHB2 Protocadherin β 2 −1.54
DNMT1 DNA (cytosine-5-)-methyltransferase 1 −1.54
S100A8 S100 calcium binding protein A8 −1.53
MAP2 Microtubule-associated protein 2 −1.53
ARRDC4 Arrestin domain containing 4 −1.52
FAM83D Family with sequence similarity 83, member D −1.52
LSR Lipolysis stimulated lipoprotein receptor −1.52
STK26 Serine/threonine protein kinase 26 −1.51
MIR181A2HG MIR181A2 host gene (non-protein coding) −1.51
VWA8 von Willebrand factor A domain containing 8 −1.51
Table 2 Genes with greater than 1.5-fold or less than −1.5-fold
expression and respective fold changes (Continued)
MEST Mesoderm-specific transcript homolog (mouse) −1.51
ZNF835 Zinc finger protein 835 1.51
NAT1 N-acetyltransferase 1 (arylamine N-acetyltransferase) 1.51
EPSTI1 Epithelial stromal interaction 1 (breast) 1.51
LOC221946 Hypothetical LOC221946 1.51
OAS1 2′,5′-oligoadenylate synthetase 1, 40/46 kDa 1.52
SELL Selectin L 1.52
COX6C Cytochrome c oxidase subunit VIc 1.52
TRIM41 Tripartite motif-containing 41 1.52
IFI27 Interferon-α-inducible protein 27 1.52
IGF1 Insulin-like growth factor 1 (somatomedin C) 1.52
SCAMP1-AS1 SCAMP1 antisense RNA 1 1.52
CD207 CD207 molecule, langerin 1.52
IFI35 Interferon-induced protein 35 1.52
GGH γ-Glutamyl hydrolase (conjugase,
folylpolygammaglutamyl hydrolase)
1.52
NOX4 NADPH oxidase 4 1.53
CNTN3 Contactin 3 (plasmacytoma associated) 1.53
CCL5 Chemokine (C-C motif) ligand 5 1.54
GALNT1 UDP-N-acetyl-α-D-galactosamine:polypeptide
N-acetylgalactosaminyltransferase 1 (GalNAc-T1)
1.54
SPON1 Spondin 1, extracellular matrix protein 1.54
SEMA3C Sema domain, immunoglobulin domain (Ig),
short basic domain, secreted, (semaphorin) 3C
1.54
DDX60L DEAD (Asp-Glu-Ala-Asp) box polypeptide 60-like 1.55
TNFSF10 Tumor necrosis factor (ligand) superfamily,
member 10
1.55
CXCL14 Chemokine (C-X-C motif) ligand 14 1.55
WISP2 WNT1 inducible signaling pathway protein 2 1.55
STAT1 Signal transducer and activator of transcription
1, 91 kDa
1.55
COMP Cartilage oligomeric matrix protein 1.56
IGLJ3 Immunoglobulin lambda joining 3 1.56
LRRC17 Leucine-rich repeat containing 17 1.56
IFI44 Interferon-induced protein 44 1.56
ISG15 ISG15 ubiquitin-like modifier 1.56
FBLN2 Fibulin 2 1.57
SLC6A6 Solute carrier family 6 (neurotransmitter
transporter, taurine), member 6
1.57
MX2 Myxovirus (influenza virus) resistance 2 (mouse) 1.57
SH3D19 SH3 domain containing 19 1.57
TRBC1 T-cell receptor β constant 1 1.58
SGCE Sarcoglycan, epsilon 1.58
IGHM Immunoglobulin heavy constant mu 1.58
DCBLD1 Discoidin, CUB and LCCL domain containing 1 1.59
PPAPDC1A Phosphatidic acid phosphatase type 2 domain
containing 1A
1.59
BST2 Bone marrow stromal cell antigen 2 1.59
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old stromal tissues. Similar results were found when we
applied GSEA to the DNA damage response gene set.
The estimated gene score was 0.57, which did not reach
statistical significance (p = 0.10) (Fig. 5b).
Senescence-associated secretory profile
Several genes involved in the SASP showed a deregulated
gene expression profile, suggesting an enrichment of SASP
in the stroma of older patients, including CXCL2 (over-
expressed in older stromal tissues; fold change 1.59),
TNFRSF11B (over-expressed in older stromal tissues; fold
change 2.11) and CCL8 (down-regulated in older stromal
tissues; fold change −1.61). Of interest, GSEA confirmed a
significant enrichment in SASP-related genes within the
stroma of older patient samples with an ES of −0.21 (p =
0.04) (Fig. 6a).
Table 2 Genes with greater than 1.5-fold or less than −1.5-fold
expression and respective fold changes (Continued)
MFAP2 Microfibrillar-associated protein 2 1.60
PDGFD Platelet-derived growth factor D 1.60
IGKC Immunoglobulin kappa constant 1.60
CST1 Cystatin SN 1.61
CCL8 Chemokine (C-C motif) ligand 8 1.61
RASGRF2 Ras protein-specific guanine nucleotide-releasing
factor 2
1.61
MX1 Myxovirus (influenza virus) resistance 1,
interferon-inducible protein p78 (mouse)
1.63
PDGFRL Platelet-derived growth factor receptor-like 1.63
ALDH1L2 Aldehyde dehydrogenase 1 family, member L2 1.63
FAM198B Family with sequence similarity 198, member B 1.63
MIR100HG Mir-100-let-7a-2 cluster host gene 1.64
GAPT GRB2-binding adaptor protein, transmembrane 1.65
SELM Selenoprotein M 1.65
DSCAM-AS1 DSCAM antisense RNA 1 1.66
STMN2 Stathmin-like 2 1.69
FBLN5 Fibulin 5 1.70
IFIT3 Interferon-induced protein with tetratricopeptide
repeats 3
1.70
SFRP4 Secreted frizzled-related protein 4 1.71
ACKR4 Atypical chemokine receptor 4 1.71
CPNE2 Copine II 1.71
PSMB9 Proteasome (prosome, macropain) subunit,
β type, 9 (large multifunctional peptidase 2)
1.72
ST6GAL2 ST6 β-galactosamide α-2,6-sialyltranferase 2 1.72
NEXN Nexilin (F actin binding protein) 1.72
CD52 CD52 molecule 1.72
MFAP5 Microfibrillar associated protein 5 1.73
RARRES3 Retinoic acid receptor responder (tazarotene
induced) 3
1.75
GXYLT2 Glucoside xylosyltransferase 2 1.75
HMCN1 Hemicentin 1 1.76
EFEMP1 EGF-containing fibulin-like extracellular matrix
protein 1
1.78
IL21R Interleukin 21 receptor 1.78
C8orf4 Chromosome 8 open reading frame 4 1.78
LINC01503 Long intergenic non-protein coding RNA 1503 1.78
OLFML3 Olfactomedin-like 3 1.79
CILP Cartilage intermediate layer protein, nucleotide
pyrophosphohydrolase
1.81
MVB12A Multivesicular body subunit 12A 1.82
SCUBE2 Signal peptide, CUB domain, EGF-like 2 1.83
WNT2 Wingless-type MMTV integration site family
member 2
1.85
APOL3 Apolipoprotein L3 1.87
ADRA2A Alpha-2A adrenergic receptor 1.89
HIST1H3I Histone cluster 1, H3i 1.92
SLC46A3 Solute carrier family 46, member 3 1.92
Table 2 Genes with greater than 1.5-fold or less than −1.5-fold
expression and respective fold changes (Continued)
ARHGAP28 Rho GTPase activating protein 28 1.93
KANK4 KN motif and ankyrin repeat domains 4 1.93
SDC1 Syndecan 1 1.95
CMPK2 Cytidine monophosphate (UMP-CMP) kinase 2,
mitochondrial
1.96
IFI44L Interferon-induced protein 44-like 1.97
FMO1 Flavin containing monooxygenase 1 1.98
TMEM119 Transmembrane protein 119 1.99
FNDC1 Fibronectin type III domain containing 1 2.00
ADAMDEC1 ADAM-like, decysin 1 2.00
TPSAB1 Tryptase α/β1 2.02
CPA3 Carboxypeptidase A3 (mast cell) 2.02
MMP3 Matrix metallopeptidase 3 (stromelysin 1,
progelatinase)
2.05
IFI6 Interferon, α-inducible protein 6 2.06
IFIT1 Interferon-induced protein with tetratricopeptide
repeats 1
2.06
SFRP2 Secreted frizzled-related protein 2 2.09
TRIM6 Tripartite motif-containing 6 2.10
TPSB2 Tryptase β2 (gene/pseudogene) 2.19
RSAD2 Radical S-adenosyl methionine domain containing 2 2.28
LOXL1 Lysyl oxidase-like 1 2.30
OMD Osteomodulin 2.35
IGJ Immunoglobulin J polypeptide, linker protein
for immunoglobulin α and mu polypeptides
2.44
FCGR1A Fc fragment of IgG, high affinity Ia, receptor (CD64) 2.47
MATN3 Matrilin 3 2.55
IGLV@ Immunoglobulin lambda variable cluster 2.65
OGN Osteoglycin 2.99
EPYC Epiphycan 3.04
Negative values for fold change indicate up-regulation in older patient
samples; positive fold change values indicate up-regulation in younger
patient samples
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The reverse Warburg effect: autophagy genes
None of the genes described to be involved in the AST
showed a relevant difference in gene expression between
young and old stroma at the individual gene level. However,
when compiling them together in the GSEA, we found
a highly significant enrichment of autophagy genes in
the stroma of older patient samples (ES −0.42; p < 0.01)
(Fig. 6b).
Discussion
The reason for the age-related increase in cancers has
been debated for decades. Besides cumulative DNA
damage throughout life, the accumulation of senescent
cells is assumed to create a tumour-promoting micro-
environment through phenomena such as the SASP and
the AST. So far, studies investigating the impact of stromal
senescence on tumour development have been based on in
vitro fibroblast cultures where senescence was artificially in-
duced [23, 29]. As a consequence of this approach, an over-
load of senescent or pre-senescent fibroblasts was present
in these experiments. We do not know if this accurately re-
flects the situation in spontaneous cancers. Accumulation
of senescent cells with age has been studied mostly in fibro-
blasts localised in the skin [14], but data on the frequency
Fig. 3 Heat maps constructed using the 25 top up-regulated and the 25 top down-regulated genes. Blue represents young patients, and green
represents old patients
Fig. 4 Venn diagrams showing the intersection of our own expression data (‘study data’) and the publicly available data (‘metadata’). a The up-regulated
genes in young stromal samples. b The down-regulated genes in young stromal samples
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of senescent fibroblasts in the older breast are lacking.
Moreover, controversy exists regarding whether findings on
in vitro senescence can be extrapolated to the situation in
vivo. We therefore aimed in this study to investigate
the molecular footprint of the older breast cancer
micro-environment in order to support in vivo con-
firmation of key concepts such as ageing/senescence,
DNA damage response, SASP and AST. Senescence in
the surrounding stroma is expected to result in a pro-
tumourigenic micro-environment with stimulation of prolif-
eration, migration/invasion and de-differentiation. However,
this had never been shown in spontaneously occurring
breast cancers. For this purpose, we selected two groups of
patients with triple-negative breast cancer belonging to ex-
treme age categories, isolated cancer-associated stromal
fields via LCM and investigated their gene expression
profiles.
Differential gene expression analysis using a cut-off of
a 1.5-fold change in expression revealed 120 up-regulated
and 107 down-regulated genes in the stromal parts of older
patients compared with the younger patients. Validation of
these findings using publicly available stromal data revealed
a set of ten differentially expressed genes between
young and old stromal samples. The young stromal
samples showed mainly up-regulation in genes such as
RARRES3, SCUBE2, SFRP4, COMP and NANT1 that
preclude migration and invasion by stabilising the cells
in the extracellular matrix and stimulate differentiation
[41, 51–60]. Significant up-regulation in the older stromal
micro-environment was shown instead for genes that are in-
volved in proliferation, de-differentiation and angiogenesis.
Four genes, namely ANXA3, PROM1, FGF13 and TUBB2B,
seem to restrain differentiation and promote cell prolif-
eration, invasiveness and metastasis [61–71]. The fifth
up-regulated gene in the older stromal samples, WIF1,
is a negative inhibitor of the Wnt (Wingless-type)/β-catenin
signalling pathway. It is thought to inhibit proliferation and
to induce differentiation and cellular senescence by up-
regulation of tumour suppressor genes such as TP53 or
P21 [72, 73]. Although the proliferation-inhibiting and
differentiation-inducing effects of this gene seem to be
Table 3 Significant up- or down-regulated genes after validation
in the external validation data set (see Fig. 4)
Gene Full name Fold
change
RARRES3 Retinoic acid receptor responder (tazarotene
induced) 3
1.75
SFRP4 Secreted frizzled-related protein 4 1.71
SCUBE2 Signal peptide, CUB domain, EGF-like 2 1.83
NAT1 N-acetyltransferase 1 (arylamine N-acetyltransferase) 1.51
COMP Cartilage oligomeric matrix protein 1.56
ANXA3 Annexin A3 −2.06
PROM1 Prominin 1 −2.27
FGF13 Fibroblast growth factor 13 −1.68
TUBB2B Tubulin, beta 2B −1.64
WIF1 WNT inhibitory factor 1 −2.10
Negative values for fold change indicate up-regulation in old patient samples,
and positive values indicate up-regulation in young patient samples
Fig. 5 Gene set enrichment analysis plots. a Senescence genes. b The DNA damage response process Low values correspond to enrichment of
the genes in older patients, and high values correspond to enrichment of the genes in younger patients. ES Enrichment score
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in contradiction with the proliferation- and metastasis-
promoting activity of the other four up-regulated genes
in the older stromal samples, its senescence-inducing
function may be an obvious explanation for the age-
related stromal expression of WIF1 in our study. Taken
together, on the basis of our data, we found evidence of
a more tumour-favourable micro-environment in the
stromal samples from older patients than in those from
younger patients.
As an additional analysis, we applied a candidate gene
approach by assembling sets of genes on the basis of
the literature. We specifically looked at the individual
gene expression results for these genes, but we also
compiled them using a gene set enrichment strategy
that reflects the representation of these genes among
the top up- or down-regulated genes in old and young
stromal samples.
The molecular process of senescence is characterised
by up-regulation of several senescence genes. The most
documented ones are TP53, CDKN2A (P16), CDKN1A
(P21) and RB [74–76]. These major senescence-inducing
genes did not show significantly different expression values
between young and old stroma in the individual gene
analysis. Nevertheless, we observed in older patients an up-
regulation of PAI-1 (SERPINE1), a matrix-remodelling en-
zyme, which has also been described as a crucial regulator
of ageing and senescence by acting downstream of TP53
and upstream of insulin-like growth factor binding protein
3 [77], and of WIF1, described above as an inhibitor of the
Wnt/β-catenin signalling pathway and an inducer of senes-
cence, and it was also significantly increased in samples
from old compared with young patients (Table 2).
These findings could be indicative of more widespread
cellular senescence in our older stromal samples compared
Fig. 6 Gene set enrichment analysis plots. a The senescence-associated secretory profile process. b The autophagy-to-senescence transition or
‘reverse Warburg effect’. Low values correspond to enrichment of the genes in older patients, and high values correspond to enrichment of the
genes in younger patients. ES Enrichment score
Table 4 Groups of candidate genes related to a specific pathophysiological process, built to perform gene set enrichment analysis,
and their respective references
Gene group Involved genes References
Cellular senescence CDKN1A, CDKN2A, TP53, RB1, GLB1 [17–19, 69–71]
DNA damage response ATM, NBN, CHEK2 [21, 73]
Senescence-associated secretory profile IL1A, IL6, IL6R, IL6ST, IL8, CXCL1, CXCL2, CXCL3, CSF2, IL7, ICAM1, TNFRSF11B, HGF, IGFBP4,
CCL8, PLAUR, IGFBP2, CCL26, IL13, CCL20, ICAM3, PGF, TNFRSF1A, TNFRSF1B, CCL13, CCL16,
TNFRSF10C, CCL2, FAS, ANG, IGFBP6, IL1B, (CCL3), TIMP2, IL11, OSM, LEP, AXL, KITLG, FGF7,
IL15, FGF2, IGFBP1, MIF
[17, 21, 22, 26]
Autophagy-to-senescence transition CAV1, CTSB, BNIP3, PRKAA1, PRKAA2, LAMP2, MAP1LC3B, ATG16L1, HIF1A, NFKB1, DRAM1,
TP73, MAPK8, E2F1, STK11
[33–37]
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with the young ones. Gene enrichment analysis based on
five key senescence genes, including the ones mentioned
above, showed a tendency towards a more prominent
senescence trait in older stroma, but no significant ES was
reached for this process in the older patient samples.
Therefore, we cannot decisively conclude that samples from
the older patient group show increased senescence.
The DNA damage response is a biological process
that, upon severe DNA damage, triggers the switch to-
wards a permanent growth arrest [78]. It was found that
the molecular senescence programme can be induced
only when this DNA damage response has been acti-
vated for a sufficiently long time period [21]. We could
not demonstrate any clear difference in the individual
expression of three key players involved in the DNA
damage response (ATM, NBN or CHEK2) [78], nor did
we find significant enrichment for this set of genes in
the older patient samples.
In our stromal gene expression study, only a few of
the SASP components described by Coppé et al. as over-
produced by senescent cell cultures [26] showed signifi-
cant age-related differential expression: CXCL2 and
osteoprotegerin (TNFRSF11B), a member of the tumour
necrosis factor receptor superfamily, which both showed
overexpression in the old patient samples, as well as
CCL8, which showed down-regulation in the older
versus the younger stromal samples. Of interest, when
compiling all the components of the SASP together in
the gene enrichment analysis, we indeed confirmed a
significant enrichment in SASP genes among genes up-
regulated in the older patient samples, confirming for
the first time the presence of the SASP phenotype in
human breast cancers in vivo.
Autophagy is assumed to precede or parallel the process
of senescence [38], as described by the term autophagy-to-
senescence transition (AST). Typical markers for AST are
loss of caveolin 1 (CAV1) and up-regulation of BNIP3,
BNIP3L, Beclin-1, Cathepsin B and ATG16L1. Our indi-
vidual gene expression results did not show relevant up-
regulation of single autophagy-related genes in the older
stromal samples, but compilation of these genes into a
GSEA showed highly significant enrichment for autoph-
agy genes in the older stromal samples. Thus, in addition
to the presence of SASP, we also confirmed the presence
of AST in the older stromal cancer milieu.
In this study, regarding gene expression levels, we report,
for the first time to our knowledge, the presence of SASP
and AST in older stromal samples, supporting the previ-
ously published in vitro and xenograft findings. This does
not, however, solve the paradox between the stimulatory
effect that these processes are supposed to have on proxim-
ate malignant cells and the clinical finding that breast can-
cer in older patients behaves in a rather more indolent
instead of a more aggressive way [79]. Also, it remains
puzzling that we found evidence for SASP and AST in
older stromal samples, which are senescence-related
phenomena, whereas we did not find convincing evi-
dence for increased senescence in these samples. The
small sample size, together with the low number of
genes defining the ‘senescence’ programme, could partly ex-
plain the lack of significance for major senescence-related
genes such as TP53, CDKN2A and pRB, both at the individ-
ual level and in the GSEAs.
Besides the small sample size of the study, the broad
age interval between the patient groups and the differ-
ence in menopausal status between the groups introduce
other potential biases, because not only the stroma but
also infiltrating immune cells are believed to be altered
by hormonal changes. Ideally, our findings would be further
investigated in larger patient cohorts including other age
categories, and validated by proteomic analysis of the stro-
mal tissue. LCM is a demanding technique, however, limit-
ing the number of patient samples that can be processed.
We attempted to compensate for some of these limitations
by including a validation strategy on publicly available gene
expression data.
Conclusions
We report, for the first time to our knowledge, the involve-
ment of key pathophysiological concepts of cancer and
ageing, such as the SASP and the AST, in vivo in human
cancer patients. These remarkable findings justify further
research to fully elucidate the role of the ageing stroma in
(breast) tumour development and progression. In the first
place, this research should be extended in other subtypes of
breast cancer and more age categories.
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